{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:09:14Z","timestamp":1793372954088,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["MH CZ - DRO (UHHK, 00179906) and PROGRES Q40\/08"],"award-info":[{"award-number":["MH CZ - DRO (UHHK, 00179906) and PROGRES Q40\/08"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s11239-020-02175-8","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T07:03:02Z","timestamp":1592895782000},"page":"112-119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Ph\u2212 myeloproliferative neoplasms and the related risk factors for stroke occurrence: Results from a registry of patients treated with Anagrelide"],"prefix":"10.1007","volume":"51","author":[{"given":"Milan","family":"Ko\u0161\u0165\u00e1l","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159\u00ed","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Ovesn\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslav","family":"Penka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Dul\u00ed\u010dek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for CZEMP\u2013Czech Group for Ph- Myeloproliferative neoplasms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,23]]},"reference":[{"key":"2175_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s11864-014-0279-3","volume":"15","author":"PJ Muxi","year":"2014","unstructured":"Muxi PJ, Oliver AC (2014) Jak-2 positive myeloproliferative neoplasms. Curr Treat Options Oncol 15:147\u2013156. https:\/\/doi.org\/10.1007\/s11864-014-0279-3","journal-title":"Curr Treat Options Oncol"},{"key":"2175_CR2","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","volume":"120","author":"T Barbui","year":"2012","unstructured":"Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Vannucchi AM, Tefferi A (2012) Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 120:5128\u20135133. https:\/\/doi.org\/10.1182\/blood-2012-07-444067","journal-title":"Blood"},{"key":"2175_CR3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/ejh.12554","volume":"96","author":"J Schwarz","year":"2016","unstructured":"Schwarz J, Ovesna P, Cerna O, Kissova J, Maaloufova Soukupova J, Brychtova Y, Doubek M, Cervinek L, Cmunt E, Dulicek P, Campr V, Kren L, Penka M (2016) Thrombosis in thrombocythemic Ph- myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide. Eur J Haematol 96:98\u2013106. https:\/\/doi.org\/10.1111\/ejh.12554","journal-title":"Eur J Haematol"},{"key":"2175_CR4","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s11910-014-0496-y","volume":"14","author":"A Artoni","year":"2014","unstructured":"Artoni A, Bucciarelli P, Martinelli I (2014) Cerebral thrombosis and myeloproliferative neoplasms. Curr Neurol Neurosci Rep 14:496. https:\/\/doi.org\/10.1007\/s11910-014-0496-y","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2175_CR5","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1365-2141.2010.08122.x","volume":"149","author":"CN Harrison","year":"2010","unstructured":"Harrison CN, Bareford D, Butt N, Campbell P, Conneally E, Drummond M, Erber W, Everington T, Green AR, Hall GW, Hunt BJ, Ludlam CA, Murrin R, Nelson-Piercy C, Radia DH, Reilly JT, Van der Walt J, Wilkins B, McMullin MF (2010) Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol 149:352\u2013375. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08122.x","journal-title":"Br J Haematol"},{"key":"2175_CR6","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kroger N, Mesa R, McMullin MF, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi A (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29:761\u2013770. https:\/\/doi.org\/10.1200\/JCO.2010.31.8436","journal-title":"J Clin Oncol"},{"key":"2175_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1055\/s-2006-939434","volume":"32","author":"J Schwarz","year":"2006","unstructured":"Schwarz J, Pytlik R, Doubek M, Brychtova Y, Dulicek P, Campr V, Kren L, Penka M (2006) Analysis of risk factors: the rationale of the guidelines of the Czech Hematological Society for diagnosis and treatment of chronic myeloproliferative disorders with thrombocythemia. Semin Thromb Hemost 32:231\u2013245. https:\/\/doi.org\/10.1055\/s-2006-939434","journal-title":"Semin Thromb Hemost"},{"key":"2175_CR8","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1200\/JCO.1990.8.3.556","volume":"8","author":"S Cortelazzo","year":"1990","unstructured":"Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T (1990) Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 8:556\u2013562. https:\/\/doi.org\/10.1200\/JCO.1990.8.3.556","journal-title":"J Clin Oncol"},{"key":"2175_CR9","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","volume":"117","author":"A Carobbio","year":"2011","unstructured":"Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Finazzi G, Gangat N, Tefferi A, Barbui T (2011) Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 117:5857\u20135859. https:\/\/doi.org\/10.1182\/blood-2011-02-339002","journal-title":"Blood"},{"key":"2175_CR10","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s00277-010-1154-3","volume":"90","author":"F Palandri","year":"2011","unstructured":"Palandri F, Polverelli N, Catani L, Ottaviani E, Baccarani M, Vianelli N (2011) Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study. Ann Hematol 90:933\u2013938. https:\/\/doi.org\/10.1007\/s00277-010-1154-3","journal-title":"Ann Hematol"},{"key":"2175_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/hon.816","volume":"25","author":"F Radaelli","year":"2007","unstructured":"Radaelli F, Colombi M, Calori R, Zilioli VR, Bramanti S, Iurlo A, Zanella A (2007) Analysis of risk factors predicting thrombotic and\/or haemorrhagic complications in 306 patients with essential thrombocythemia. Hematol Oncol 25:115\u2013120. https:\/\/doi.org\/10.1002\/hon.816","journal-title":"Hematol Oncol"},{"key":"2175_CR12","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","volume":"110","author":"A Tefferi","year":"2007","unstructured":"Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110:1092\u20131097. https:\/\/doi.org\/10.1182\/blood-2007-04-083501","journal-title":"Blood"},{"key":"2175_CR13","first-page":"189","volume":"57","author":"J Schwarz","year":"2011","unstructured":"Schwarz J, Penka M, Campr V, Pospisilova D, Kren L, Novakova L, Bodzasova C, Brychtova Y, Cerna O, Dulicek P, Joniasova A, Kissova J, Koristek Z, Schutzova M, Vonke I, Walterova L (2011) Diagnosis and treatment of BCR\/ABL-negative myeloproliferative diseases\u2013principles and rationale of CZEMP recommendations. Vnitr Lek 57:189\u2013213","journal-title":"Vnitr Lek"},{"key":"2175_CR14","first-page":"29","volume":"34","author":"S Murphy","year":"1997","unstructured":"Murphy S, Peterson P, Iland H, Laszlo J (1997) Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 34:29\u201339","journal-title":"Semin Hematol"},{"key":"2175_CR15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.clml.2011.10.002","volume":"12","author":"HS Lee","year":"2012","unstructured":"Lee HS, Park LC, Lee EM, Lee SJ, Shin SH, Im H, Do KM, Kim EJ, Ye BJ, Song MK, Kim SH, Lee SM, Lee WS, Kim YS (2012) Incidence rates and risk factors for vascular events in patients with essential thrombocythemia: a multicenter study from Korea. Clin Lymphoma Myeloma Leukemia 12:70\u201375. https:\/\/doi.org\/10.1016\/j.clml.2011.10.002","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"2175_CR16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/jama.289.3.343","volume":"289","author":"AT Schneider","year":"2003","unstructured":"Schneider AT, Pancioli AM, Khoury JC, Rademacher E, Tuchfarber A, Miller R, Woo D, Kissela B, Broderick JP (2003) Trends in community knowledge of the warning signs and risk factors for stroke. JAMA J Am Med Assoc 289:343\u2013346","journal-title":"JAMA J Am Med Assoc"},{"key":"2175_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3988\/jcn.2014.10.1.1","volume":"10","author":"L Nobel","year":"2014","unstructured":"Nobel L, Mayo NE, Hanley J, Nadeau L, Daskalopoulou SS (2014) MyRisk_Stroke calculator: a personalized stroke risk assessment tool for the general population. J Clin Neurol 10:1\u20139. https:\/\/doi.org\/10.3988\/jcn.2014.10.1.1","journal-title":"J Clin Neurol"},{"key":"2175_CR18","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1161\/01.STR.22.3.312","volume":"22","author":"PA Wolf","year":"1991","unstructured":"Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB (1991) Probability of stroke: a risk profile from the Framingham Study. Stroke 22:312\u2013318","journal-title":"Stroke"},{"key":"2175_CR19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.pjnns.2017.11.007","volume":"52","author":"Z Pastuszak","year":"2018","unstructured":"Pastuszak Z, Kozniewska E, Stepien A, Piusinska-Macoch A, Czernicki Z, Koszewski W (2018) Importance rating of risk factors of ischemic stroke in patients over 85 years old in the polish population. Neurol Neurochir Pol 52:88\u201393. https:\/\/doi.org\/10.1016\/j.pjnns.2017.11.007","journal-title":"Neurol Neurochir Pol"},{"key":"2175_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2017.11.003","author":"SE Kjeldsen","year":"2017","unstructured":"Kjeldsen SE (2017) Hypertension and cardiovascular risk: general aspects. Pharmacol Res. https:\/\/doi.org\/10.1016\/j.phrs.2017.11.003","journal-title":"Pharmacol Res"},{"key":"2175_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1177\/1747493016672083","volume":"12","author":"L Sanchez-Inigo","year":"2017","unstructured":"Sanchez-Inigo L, Navarro-Gonzalez D, Fernandez-Montero A, Pastrana-Delgado J, Martinez JA (2017) Risk of incident ischemic stroke according to the metabolic health and obesity states in the Vascular-Metabolic CUN cohort. Int J Stroke 12:187\u2013191. https:\/\/doi.org\/10.1177\/1747493016672083","journal-title":"Int J Stroke"},{"key":"2175_CR22","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1586\/ern.10.104","volume":"10","author":"LM de Lau","year":"2010","unstructured":"de Lau LM, Leebeek FW, de Maat MP, Koudstaal PJ, Dippel DW (2010) Screening for coagulation disorders in patients with ischemic stroke. Expert Rev Neurotherapeutics 10:1321\u20131329. https:\/\/doi.org\/10.1586\/ern.10.104","journal-title":"Expert Rev Neurotherapeutics"},{"key":"2175_CR23","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1161\/CIRCULATIONAHA.109.913673","volume":"121","author":"G Kenet","year":"2010","unstructured":"Kenet G, Lutkhoff LK, Albisetti M, Bernard T, Bonduel M, Brandao L, Chabrier S, Chan A, deVeber G, Fiedler B, Fullerton HJ, Goldenberg NA, Grabowski E, Gunther G, Heller C, Holzhauer S, Iorio A, Journeycake J, Junker R, Kirkham FJ, Kurnik K, Lynch JK, Male C, Manco-Johnson M, Mesters R, Monagle P, van Ommen CH, Raffini L, Rostasy K, Simioni P, Strater RD, Young G, Nowak-Gottl U (2010) Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies. Circulation 121:1838\u20131847. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.913673","journal-title":"Circulation"},{"key":"2175_CR24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/NRL.0000000000000110","volume":"22","author":"VV Montanaro","year":"2017","unstructured":"Montanaro VV, Freitas DD, Ruiz MC, Cavalcanti EB, Marinho PB, Freitas MC, Oliveira EM (2017) Ischemic stroke in young adults: profile of SARAH Hospital Brasilia from 2008 to 2012. Neurologist 22:61\u201363. https:\/\/doi.org\/10.1097\/NRL.0000000000000110","journal-title":"Neurologist"},{"key":"2175_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/1076029617727857","author":"P Dulicek","year":"2017","unstructured":"Dulicek P, Ivanova E, Kostal M, Sadilek P, Beranek M, Zak P, Hirmerova J (2017) Analysis of risk factors of stroke and venous thromboembolism in females with oral contraceptives use. Clin Appl Thromb. https:\/\/doi.org\/10.1177\/1076029617727857","journal-title":"Clin Appl Thromb"},{"issue":"1","key":"2175_CR26","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/S0049-3848(17)30066-X","volume":"151","author":"R Cervera","year":"2017","unstructured":"Cervera R (2017) Antiphospholipid syndrome. Thromb Res 151(1):S43\u2013S47. https:\/\/doi.org\/10.1016\/S0049-3848(17)30066-X","journal-title":"Thromb Res"},{"key":"2175_CR27","first-page":"1319","volume":"65","author":"H Okuma","year":"2013","unstructured":"Okuma H, Kitagawa Y (2013) Diagnosis and potential treatment of antiphospholipid syndrome-related mainly on ischemic stroke. Brain Nerve 65:1319\u20131332","journal-title":"Brain Nerve"},{"key":"2175_CR28","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1043\/1543-2165(2007)131[890:HTIIS]2.0.CO;2","volume":"131","author":"A Rahemtullah","year":"2007","unstructured":"Rahemtullah A, Van Cott EM (2007) Hypercoagulation testing in ischemic stroke. Arch Pathol Lab Med 131:890\u2013901. https:\/\/doi.org\/10.1043\/1543-2165(2007)131[890:HTIIS]2.0.CO;2","journal-title":"Arch Pathol Lab Med"},{"key":"2175_CR29","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/ejh.12759","volume":"97","author":"V Buxhofer-Ausch","year":"2016","unstructured":"Buxhofer-Ausch V, Steurer M, Sormann S, Schloegl E, Schimetta W, Gisslinger B, Ruckser R, Gastl G, Gisslinger H (2016) Influence of platelet and white blood cell counts on major thrombosis-analysis from a patient registry in essential thrombocythemia. Eur J Haematol 97:511\u2013516. https:\/\/doi.org\/10.1111\/ejh.12759","journal-title":"Eur J Haematol"},{"key":"2175_CR30","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1182\/blood-2008-04-153783","volume":"112","author":"A Carobbio","year":"2008","unstructured":"Carobbio A, Finazzi G, Antonioli E, Guglielmelli P, Vannucchi AM, Delaini F, Guerini V, Ruggeri M, Rodeghiero F, Rambaldi A, Barbui T (2008) Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood 112:3135\u20133137. https:\/\/doi.org\/10.1182\/blood-2008-04-153783","journal-title":"Blood"},{"issue":"1","key":"2175_CR31","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3109\/10428199609074364","volume":"22","author":"PJ van Genderen","year":"1996","unstructured":"van Genderen PJ, Leenknegt H, Michiels JJ, Budde U (1996) Acquired von Willebrand disease in myeloproliferative disorders. Leuk Lymphoma 22(1):79\u201382. https:\/\/doi.org\/10.3109\/10428199609074364","journal-title":"Leuk Lymphoma"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-020-02175-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-020-02175-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-020-02175-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T23:34:22Z","timestamp":1624404862000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-020-02175-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,23]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["2175"],"URL":"https:\/\/doi.org\/10.1007\/s11239-020-02175-8","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,23]]},"assertion":[{"value":"23 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MK receives a speaker \u2018s honoraria from Novartis, AOP Orphan Pharmaceuticals. JS has received speaker \u2018s and consultancy honoraria from AOP Orphan Pharmaceuticals. MP receives speaker \u2018s and consultancy honoraria from AOP Orphan Pharmaceuticals AG and Novartis. PD receives speaker\u2019s and consultancy honoraria from AOP Orphan Pharmaceuticals. P.O. has no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All authors read the manuscript and agree with its publication in the Journal of Thrombosis and Thrombolysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}